Posted by Michael Wonder on 27 Jan 2023
Risankizumab for the treatment of patients with previously treated moderate to severe active Crohn's disease
27 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using risankizumab in the NHS in England.
Risankizumab is not recommended for the treatment of patients 16 years and over with moderate to severe active Crohn's disease that has not responded well enough or lost response to conventional treatment or a biological treatment, or when these treatments are not tolerated or suitable.
